Department of Pharmacology and Toxicology, Georgia Regents University , Augusta, GA , USA.
Front Immunol. 2013 Jul 29;4:219. doi: 10.3389/fimmu.2013.00219. eCollection 2013.
Enhanced arginase (ARG) activity has been identified as a factor that reduces nitric oxide production and impairs endothelial function in vascular pathologies. Using a gene deletion model, we investigated involvement of arginase isoforms arginase 1 and 2 (ARG1 and ARG2) in hypertension and endothelial dysfunction in a mineralocorticoid-salt mouse model. Hypertension was induced in wild type (WT), partial ARG1(+/-) knockout (KO), and complete ARG2(-/-) KO mice by uninephrectomy and deoxycorticosterone acetate (DOCA)-salt treatment for 6-weeks. (Control uninephrectomized mice drank tap water.) After 2 weeks of DOCA-salt treatment, systolic blood pressure (SBP) was increased by ∼15 mmHg in all mouse genotypes. SBP continued to rise in DOCA-salt WT and ARG2(-/-) mice to ∼130 mmHg at 5-6 weeks, whereas in ARG1(+/-) mice SBP waned toward control levels by 6 weeks (109 ± 4 vs. 101 ± 3 mmHg, respectively). DOCA-salt treatment in WT mice increased vascular ARG activity (aorta by 1.5-fold; mesenteric artery (MA) by 2.6-fold and protein levels of ARG1 (aorta: 1.49-fold and MA: 1.73-fold) vs. WT Sham tissues. ARG2 protein increased in WT-DOCA MA (by 2.15-fold) but not in aorta compared to those of WT Sham tissues. Maximum endothelium-dependent vasorelaxation to acetylcholine was significantly reduced in DOCA-salt WT mice and largely or partially maintained in DOCA ARG1(+/-) and ARG2(-/-) mice vs. their Sham controls. DOCA-salt augmented contractile responses to phenylephrine in aorta of all mouse genotypes. Additionally, treatment of aorta or MA from WT-DOCA mice with arginase inhibitor (100 μM) improved endothelium-mediated vasorelaxation. DOCA-salt-induced coronary perivascular fibrosis (increased by 2.1-fold) in WT was prevented in ARG1(+/-) and reduced in ARG2(-/-) mice. In summary, ARG is involved in murine DOCA-salt-induced impairment of vascular function and hypertension and may represent a novel target for antihypertensive therapy.
精氨酸酶(ARG)活性增强已被确定为减少血管病变中一氧化氮产生和损害内皮功能的因素。我们使用基因缺失模型,研究了血管紧张素原 1 和 2(ARG1 和 ARG2)同工酶在醛固酮-盐小鼠模型中的高血压和内皮功能障碍中的作用。通过单侧肾切除术和脱氧皮质酮乙酸盐(DOCA)-盐处理,在野生型(WT)、部分 ARG1(+/-)敲除(KO)和完全 ARG2(-/-) KO 小鼠中诱导高血压 6 周。(对照单侧肾切除小鼠饮用自来水。)在 DOCA-盐处理 2 周后,所有小鼠基因型的收缩压(SBP)升高约 15mmHg。在 DOCA-salt WT 和 ARG2(-/-)小鼠中,SBP 继续升高至 5-6 周时约 130mmHg,而在 ARG1(+/-)小鼠中,SBP 在 6 周时向对照水平下降(分别为 109±4mmHg 和 101±3mmHg)。在 WT 小鼠中,DOCA-盐处理增加了血管 ARG 活性(主动脉增加 1.5 倍;肠系膜动脉(MA)增加 2.6 倍,ARG1 蛋白水平(主动脉:增加 1.49 倍;MA:增加 1.73 倍)与 WT Sham 组织相比。与 WT Sham 组织相比,WT-DOCA MA 中的 ARG2 蛋白增加(增加 2.15 倍),但主动脉中未增加。与各自的 Sham 对照相比,乙酰胆碱诱导的最大内皮依赖性血管舒张在 DOCA-salt WT 小鼠中显著降低,但在 DOCA-ARG1(+/-)和 ARG2(-/-)小鼠中基本或部分维持。DOCA-salt 增强了所有小鼠基因型主动脉对苯肾上腺素的收缩反应。此外,用精氨酸酶抑制剂(100μM)处理来自 WT-DOCA 小鼠的主动脉或 MA 可改善内皮介导的血管舒张。WT 中 DOCA-salt 诱导的冠状血管周围纤维化(增加 2.1 倍)在 ARG1(+/-)中被预防,在 ARG2(-/-)中被减少。总之,ARG 参与了小鼠 DOCA-salt 诱导的血管功能障碍和高血压,可能成为抗高血压治疗的新靶点。